Peptide Stapling Technology Enables Oral Delivery of Macrocyclic Therapeutics
New research demonstrates that hydrocarbon-stapled peptides can achieve oral bioavailability exceeding 20%, potentially transforming peptide therapeutic development.
Researchers have published breakthrough findings demonstrating that peptide stapling technology can enable oral bioavailability exceeding 20% for certain macrocyclic peptides, far surpassing what was previously thought achievable. The advance could fundamentally change the therapeutic potential of peptide drugs.
What We Know
The study examined a series of hydrocarbon-stapled peptides designed to inhibit protein-protein interactions involved in cancer progression. Through systematic optimization of staple chemistry, peptide sequence, and N-terminal modifications, researchers identified compounds with oral bioavailability ranging from 18% to 24% in rodent models [stapled-peptide-oral].
Key design principles emerged from the research. Successful oral peptides had molecular weights below 1,000 Daltons, contained multiple N-methylated amide bonds to reduce hydrogen bond donors, and featured the hydrocarbon staple positioned to shield the peptide backbone from proteolytic degradation.
Plasma half-lives after oral dosing ranged from 8-12 hours, supporting once or twice-daily dosing regimens. The compounds demonstrated good distribution to tumor tissue and achieved target engagement at pharmacologically relevant concentrations [macrocycle-design].
Stapling Technology
Peptide stapling involves introduction of a covalent crosslink (the “staple”) between amino acid side chains, typically using hydrocarbon linkers. This constrains the peptide into a specific three-dimensional shape, often an alpha-helix, while simultaneously protecting it from proteolytic enzymes.
The technology was originally developed to enhance binding to protein targets and improve resistance to degradation for injectable peptides. The current work extends the benefits to oral administration, addressing the poor absorption that has limited peptide therapeutics to parenteral delivery.
The staple itself appears to play dual roles: constraining the peptide backbone reduces conformational flexibility (decreasing entropic cost of absorption), while the hydrocarbon nature increases lipophilicity and membrane permeability.
What It Means
If the findings translate to human pharmacokinetics, stapled peptides could compete with small molecules for oral drug development while accessing targets that small molecules cannot efficiently modulate. Protein-protein interactions, traditionally considered undruggable, are particularly amenable to peptide-based approaches.
The achievement of 20%+ oral bioavailability crosses an important threshold. While lower than typical small molecule drugs (often 40-80%), this level is sufficient for viable oral therapeutics, as demonstrated by numerous approved drugs with bioavailability in this range.
Pharmaceutical company interest in stapled peptides has intensified. Several oral stapled peptide programs are now advancing toward clinical development, with first-in-human studies planned for 2026 [clinical-stapled].
Manufacturing considerations remain important. Stapled peptides are more complex to synthesize than linear peptides, requiring additional chemical steps to introduce the crosslink. However, production costs have decreased as manufacturing expertise has grown.
What’s Next
Multiple companies are racing to bring oral stapled peptides to clinical testing. Oncology applications dominate current pipelines, with programs targeting p53-MDM2, BH3 family proteins, and various transcription factors involved in cancer.
Optimization of staple chemistry continues. While hydrocarbon staples are most advanced, alternative crosslinking chemistries may offer improved properties. Photochemical stapling, triazole linkages, and other approaches are under investigation.
The broader implications extend to peptide drug development generally. Success with oral stapled peptides would validate the strategy of using chemical modification to overcome traditional peptide limitations, encouraging similar innovation for other peptide classes.
Regulatory pathways for stapled peptides are being clarified through interactions with the FDA. These modified peptides occupy novel chemical space between traditional peptides and small molecules, requiring regulatory science to define appropriate development and evaluation approaches.
This information is provided for educational purposes only and does not constitute medical advice.
Sources & Citations
- 1
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.